ARES-SERONO PHARMACEUTICAL SALES GROW 19% IN FIRST QUARTER LED BY FERTILITY LINE

Ares-Serono Group's pharmaceutical business generated a 19.2% sales increase to $172.3 mil. during the first quarter of 1992. The company noted that first quarter sales growth was paced by infertility and pediatric endocrinology sales which grew by "more than 25%" compared to the same period last year. Pharmaceutical sales were "particularly strong in the U.S., Germany, France and Japan," Ares-Serono reported. Ares-Serono corporate sales grew 15.5% in the first quarter to $198 mil. First quarter sales growth was over 20% if unfavorable currency fluctuations are excluded, the company said. Net income from continuing operations grew 25% to $16.6 mil. in the first quarter. Including extraordinary revenue from the sale of the company's OTC business in Europe to American Home Products in March, first quarter net income totaled $44.7 mil. Diagnostic product sales declined 4.1% in the first quarter to $25.7 mil. Ares-Serono said it is discontinuing its clinical chemistry product line "in order to improve the division's gross margin." Hawthorne, N.Y.-based Taro Vit reported first quarter sales of $5.7 mil., up 23% over the same period of 1991. Net income, however, declined 19% to $517,000 "due to a significant acceleration of...generic drug research and development programs," the company said. Taro Vit reported that it currently has 17 ANDAs pending at FDA. "For certain of these products," the company added, "there are no known generic drug versions currently being marketed in the U.S."

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.